Incretin Atlas › Trials › CT-388-104 (T2D)
CT-388-104 (T2D)
CT-388 · t2d
Design
- Molecule(s)
- CT-388
- Population
- t2d
- Phase
- 2
- Duration
- 48 weeks
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| enicepatide 24 mg | t2d | 48 | — | — | —−15.5 % estimand not specified | −2.6 | — | — | — | — | — | — | press release |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Notes
- enicepatide 24 mg: Topline release: placebo results not disclosed; estimand not stated.
Verbatim quotes from the source (1)
- enicepatide 24 mg · weight_unsp · company announcement
The mean weight loss at 48 weeks in the 24 mg enicepatide arm was 15.5
Primary sources
How to cite this page
Medical Adviser's Group. Incretin Atlas: CT-388-104 (T2D). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/ct-388-104/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.